This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 17.65% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 213.04% and 96.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.
Are Options Traders Betting on a Big Move in Bio-Rad Laboratories (BIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.
Bio-Rad Laboratories (BIO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $377.68, marking a +0.09% move from the previous day.
Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed at $364.38 in the latest trading session, marking a -0.37% move from the prior day.
Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed at $364.78 in the latest trading session, marking a -0.46% move from the prior day.
Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed the most recent trading day at $376.56, moving -0.66% from the previous trading session.
Bio-Rad Laboratories (BIO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $361.03, marking a +0.43% move from the previous day.
Perrigo (PRGO) Down 7.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bio-Rad Laboratories (BIO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $372.36, marking a +0.27% move from the previous day.
Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses
by Zacks Equity Research
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
What to do with the Real Estate sector?
by John Blank
Shorts have been pounding away. Where to from here?
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Bio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.